About the Authors
- Mariana López-Góngora
-
Affiliations Multiple Sclerosis Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Departament de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain, Multiple Sclerosis Research Group, Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain
- Antonio Escartín
-
* E-mail: aescartin@santpau.cat
Affiliations Multiple Sclerosis Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Departament de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain, Multiple Sclerosis Research Group, Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain
- Saul Martínez-Horta
-
Affiliations Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Parkinson’s Disease and Movement Disorders Research Group, Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain
- Ramón Fernández-Bobadilla
-
Affiliations Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Parkinson’s Disease and Movement Disorders Research Group, Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain
- Luis Querol
-
Affiliations Multiple Sclerosis Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Multiple Sclerosis Research Group, Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain
- Sergio Romero
-
Affiliations Department of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politècnica de Catalunya, BarcelonaTech (UPC), Barcelona, Spain, CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain
- Miquel Àngel Mañanas
-
Affiliations Department of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politècnica de Catalunya, BarcelonaTech (UPC), Barcelona, Spain, CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain
- Jordi Riba
-
Affiliations Human Neuropsychopharmacology Group, Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain, Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain
Competing Interests
The authors’ research group received funding from Bayer Hispania SL to conduct this study. There are no other competing interests. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: ML-G AE LQ SM-H RF-B JR. Performed the experiments: ML-G SM-H RF-B. Analyzed the data: ML-G SM-H RF-B SR MAM JR. Contributed reagents/materials/analysis tools: SR MAM JR. Wrote the paper: ML-G AE SM-H RF-B LQ SR MAM JR.